Evaluating the re-identification risk of a clinical study report anonymized under EMA Policy 0070 and Health Canada Regulations.
Janice BransonNathan GoodJung-Wei ChenWill MongeChristian ProbstKhaled El EmamPublished in: Trials (2020)
These results suggest that the anonymization guidance from these agencies can provide adequate privacy protection for patients, and the modes of attack can inform further refinements of the methodologies they recommend in their guidance for manufacturers.